the India Investment Centre copies of which are available in the Parliament Library.

(d) These details are not available.

(e) According to the available information, apart from M|s. Hoechst (India) Limited, M|s. Albert David and Suneeta Chemicals are producing Tolbutamide and M|s. Searle (India) Limited have produced small quantity of Pheniramine Maleate. Details of stage of manufacture are not known.

Action against M|s. Warner Hindustan

2180. DR. JOSEPH LEON D'SOUZA: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 184 given in the Rajya Sabha on the 18th November, 1985 and state:

(a) whether it is a fact that Government have not taken any action against M|s. Warner Hindustan as provided under provision 29 of Drugs Price Control Order for the violation of the provisions of DPCO. 1979; and

(b) if so, what are the reasons therefor?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) and (b) Position has already been explained in reply to Rajya Sabha Starred Question No. 19 answered on 18th November, 1985.

Approval of multipurpose plants by M|s Hoechst

2181. SHRI NAND KISHORE BHATT: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 180 given in the Rajya Sabha on the 18th November, 1985 and state:

(a) whether the installation of six multipurpose plants by Hoechst was done with Government's approval;

(b) if so, when was the approval of each plan sought by the company;

(c) whether Hoechst is licensed to produce any other bulk drug apart from six being monitored by Government;

(d) if so, names of the bulk drugs along with permitted capacity and stage of manufacture of those bulk drugs allowed;

(e) whether it is a fact that re-endorsement of capacity of Pheniramine Maleate was done with a condition to produce from basic stages;

(f) if so, what are the details of such conditions;

(g) what are the names of other drugs for which re-endorsement of capacity was done along with original and re-endorsed capacity in each case;

(h) whether any condition was imposed while granting re-endorsement of capacity; and

(i) if so, what are the details thereof?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) and (b) Industrial approvals are granted for the manufacture of individual bulk drugs and not in terms of plants. The question of Government approval for multipurpose plant would therefore not arise.

(c) Yes, Sir.

(d) Details of the bulk drugs manufactured to the extent available are furnished in the statement (*See below*)

(e) No capacity has been re-endorsed for Pheniramine Maleate under the existing Policy.

(f) Does not arise.

(g) Details sought are as under:

	Name of the bulk drug	Original capacity	Re-endorsed capacity
(1)	Baralgon Ketone	500 Kgs.	2489 Kgs.
(2)	Frusemide	1200 Kgs.	7148 Kgs.
(3)	Control Serum for tripartigen plates	2000 Nos. x 0.5 mls.	3344 Nos. x 0.5 mls.
(4)	Glybenclamide	200 Kgs.	897 Kgs.